Get informed when a big investor buys or sells
+ Follow-215.34%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
BioVie (BIVIW) currently reports a ROE of -215.34%. That is below the Healthcare sector average of -75.84%. Use the charts on this page to explore BioVie's ROE history and peer comparisons.
BioVie's ROE of -215.34% is lower than the Healthcare sector average of -75.84%. That is roughly 184.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but BioVie's current -215.34% should be judged against Healthcare norms (sector average: -75.84%) and against BIVIW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -215.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for BioVie, and consider following BIVIW for alerts when major investors trade the stock.
BioVie is classified in the Healthcare sector. On ROE, it currently shows -215.34% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIVIW with unrelated industries.